专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070021332A1 Helminth-derived antigens having capacity of providing protection against parasites 有权
标题翻译：蠕虫衍生的抗原具有提供针对寄生虫的保护的能力
公开(公告)号：US20070021332A1
公开(公告)日：2007-01-25
申请号：US10544035
申请日：2004-01-30
申请人： Miriam Tendler , Naftale Katz , Andrew Simpson , Isaias Raw , Paulo Ho , Celso Ramos
发明人： Miriam Tendler , Naftale Katz , Andrew Simpson , Isaias Raw , Paulo Ho , Celso Ramos
IPC分类号： A61K38/17 , C07K14/435 , G01N33/569
CPC分类号： C07K14/43559 , A61K38/00 , A61K39/00 , G01N33/56905
摘要： The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the present invention was similar to that reached in the parasite saline extract. The mutant proteins of the present invention have reached approximately 100% of renaturation after the heating at 80° C., different from wild forms of the Sm14 protein. Moreover, after storage for 2 months at 4° C., mutant proteins have shown smaller β-structure loss than wild forms that have shown formation with random structure, as demonstrated by the circular dichroism analysis, indicating the success of mutations.
摘要翻译：本发明的主要目的是开发新的突变形式的Sm14蛋白，用于产生更大的产量。这里获得的重组蛋白能够提供针对血吸虫病和fasciola感染的保护。在本发明中获得的Sm14重组蛋白的保护水平与寄生盐水提取物中达到的相似。本发明的突变型蛋白质在80℃加热后与Sm14蛋白的野生型不同，达到约100％的复性。此外，在4℃下保存2个月后，突变蛋白质显示比野生形式更小的β-结构损失，其显示出随机结构的形成，如通过圆二色性分析所证实的，表明突变的成功。

2. 发明授权

US07534437B2 Helminth-derived antigens having capacity of providing protection against parasites 有权
标题翻译：蠕虫衍生的抗原具有提供针对寄生虫的保护的能力
公开(公告)号：US07534437B2
公开(公告)日：2009-05-19
申请号：US10544035
申请日：2004-01-30
申请人： Miriam Tendler , Naftale Katz , Andrew J. Simpson , Isaias Raw , Paulo Lee Ho , Celso Raul Romero Ramos
发明人： Miriam Tendler , Naftale Katz , Andrew J. Simpson , Isaias Raw , Paulo Lee Ho , Celso Raul Romero Ramos
IPC分类号： A61K39/00 , A61K49/00 , A61K39/38 , A61K39/02
CPC分类号： C07K14/43559 , A61K38/00 , A61K39/00 , G01N33/56905
摘要： The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the present invention was similar to that reached in the parasite saline extract. The mutant proteins of the present invention have reached approximately 100% of renaturation after the heating at 80° C., different from wild forms of the Sm14 protein. Moreover, after storage for 2 months at 4° C., mutant proteins have shown smaller β-structure loss than wild forms that have shown formation with random structure, as demonstrated by the circular dichroism analysis, indicating the success of mutations.
摘要翻译：本发明的主要目的是开发新的突变形式的Sm14蛋白，用于产生更大的产量。这里获得的重组蛋白能够提供针对血吸虫病和fasciola感染的保护。在本发明中获得的Sm14重组蛋白的保护水平与寄生盐水提取物中达到的相似。本发明的突变型蛋白质在80℃加热后与Sm14蛋白的野生型不同，达到约100％的复性。此外，在4℃下保存2个月后，突变蛋白质显示比野生形式更小的β-结构损失，其显示出随机结构的形成，如通过圆二色性分析所证实的，表明突变的成功。

3. 发明申请

US20130243810A1 SYNERGISTIC IMMUNOGENIC COMPOSITIONS BASED ON PROTEIN ANTIGENS COMBINED WITH PERTUSSIS CELL ANTIGEN AND INACTIVATED TOXINS 审中-公开
标题翻译：基于与PERTUSSIS细胞抗原和灭活毒素组合的蛋白抗原的协同免疫组化
公开(公告)号：US20130243810A1
公开(公告)日：2013-09-19
申请号：US13876746
申请日：2011-09-26
申请人： Eliane Namie Miyaji , Isaias Raw , Maria Leonor Sarno de Oliveira , Paulo Lee Ho
发明人： Eliane Namie Miyaji , Isaias Raw , Maria Leonor Sarno de Oliveira , Paulo Lee Ho
IPC分类号： A61K39/116
CPC分类号： A61K39/116 , A61K39/08 , A61K39/092 , A61K39/099 , A61K2039/521 , A61K2039/543 , A61K2039/70
摘要： The present invention relates to synergistic immunogenic compositions for preventing whooping cough and infections caused by Streptococcus pneumoniae. Additionally, the compositions according to the present invention may protect against infections caused by other pathogenic agents by means of a synergistic combination of antigens thereof. In particular, the present invention provides synergistic immunogenic compositions that comprise at least one cell antigen of inactivated Bordetella pertussis and at least one protein antigen comprising one or more surface proteins A (PspA) of Streptococcus penumoniae or fragments thereof. The present invention further provides synergistic immunogenic compositions comprising at least one cell antigen of inactivated Bordetella pertussis, at least one protein antigen comprising one or more surface proteins A (PspA) of Streptococcus penumoniae or fragments thereof, and one or more diphtheria and/or tetanus toxins. The present invention also relates to the use of one or more synergistic immunogenic compositions according to the present invention for producing combined vaccines for the prevention of whooping cough, tetanus, diphtheria and/or infections caused by Streptococcus pneumoniae. The present invention further relates to the use of the compositions according to the present invention for producing vaccines for the prevention of whooping cough, tetanus, diphtheria and/or infections caused by Streptococcus pneumoniae.
摘要翻译：本发明涉及用于预防百日咳和由肺炎链球菌引起的感染的协同免疫原性组合物。另外，根据本发明的组合物可以通过其抗原的协同组合来防止由其它病原体引起的感染。特别地，本发明提供了协同免疫原性组合物，其包含灭活的百日咳博德特氏菌的至少一种细胞抗原和至少一种包含一种或多种慢性链球菌的表面蛋白A（PspA）或其片段的蛋白质抗原。本发明进一步提供包含灭活的百日盛博茨特氏菌的至少一种细胞抗原的协同免疫原性组合物，至少一种蛋白质抗原，其包含一种或多种慢性链球菌或其片段的表面蛋白A（PspA）和一种或多种白喉和/或破伤风毒素本发明还涉及根据本发明的一种或多种协同免疫原性组合物用于生产用于预防由肺炎链球菌引起的百日咳，破伤风，白喉和/或感染的组合疫苗的用途。本发明还涉及根据本发明的组合物用于生产预防由肺炎链球菌引起的百日咳，破伤风，白喉和/或感染的疫苗的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式